tamoxifen

Summary

Summary: One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS, it is agonist for bone tissue and cholesterol metabolism but antagonist in mammary and uterine tissues. Concern has been raised about increased cancer risk.

Top Publications

  1. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
  2. pmc Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
    Christina Davies
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, UK
    Lancet 381:805-16. 2013
  3. pmc ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands
    Willem Jan Welboren
    Department of Molecular Biology, Faculty of Science, Nijmegen Centre for Molecular Life Sciences, Radboud University, Nijmegen, The Netherlands
    EMBO J 28:1418-28. 2009
  4. ncbi Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase
    P S Danielian
    Department of Molecular and Cellular Biology Harvard University 16 Divinity Avenue, Cambridge Massachusetts 02138 USA
    Curr Biol 8:1323-6. 1998
  5. ncbi Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1371-88. 1998
  6. pmc MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
    Tyler E Miller
    Department of Molecular and Cellular Biochemistry, College of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 283:29897-903. 2008
  7. ncbi Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    J Clin Oncol 30:2718-24. 2012
  8. ncbi Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse
    Shigemi Hayashi
    Department of Molecular and Cellular Biology, Harvard University, 16 Divinity Avenue, Cambridge, Massachusetts 02138, USA
    Dev Biol 244:305-18. 2002
  9. ncbi Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 28:509-18. 2010
  10. ncbi American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 28:3784-96. 2010

Research Grants

  1. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2006
  2. Transcription factors regulating sensory gene expression and pain pathways
    Eric E Turner; Fiscal Year: 2011
  3. Development of VN/14-1 and Related Analogs for Breast Cancer Therapy
    VINCENT COLLINS OFUKA NJAR; Fiscal Year: 2013
  4. Transgenesis and Xenotransplantation
    Jorge A Piedrahita; Fiscal Year: 2013
  5. Metabolic mechanisms of antiestrogen resistance in breast cancer
    UBALDO EMILIO MARTINEZ OUTSCHOORN; Fiscal Year: 2013
  6. Regulation of Islet Beta-Cell Function via Islet-Derived VGF Peptides
    SAMUEL BRANDON STEPHENS; Fiscal Year: 2013
  7. P38 MAP KINASE SIGNALING IN SKIN
    Tatiana Efimova; Fiscal Year: 2013
  8. Inducible Macrophage Specific Gene Expression in Diseases
    JEANINE M D apos ARMIENTO; Fiscal Year: 2010
  9. Endocrine Targets for Prevention of Lung Cancer
    Robert M Bigsby; Fiscal Year: 2012
  10. Mechanism and therapy for arteriovenous malformation
    Suk Paul Oh; Fiscal Year: 2013

Detail Information

Publications334 found, 100 shown here

  1. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  2. pmc Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
    Christina Davies
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, UK
    Lancet 381:805-16. 2013
    For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis...
  3. pmc ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands
    Willem Jan Welboren
    Department of Molecular Biology, Faculty of Science, Nijmegen Centre for Molecular Life Sciences, Radboud University, Nijmegen, The Netherlands
    EMBO J 28:1418-28. 2009
    ..and to profile changes in RNA polymerase II (RNAPII) occupancy in MCF-7 cells in response to estradiol (E2), tamoxifen or fulvestrant...
  4. ncbi Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase
    P S Danielian
    Department of Molecular and Cellular Biology Harvard University 16 Divinity Avenue, Cambridge Massachusetts 02138 USA
    Curr Biol 8:1323-6. 1998
    ..Here, we assessed whether a tamoxifen-inducible form of Cre recombinase (Cre-ERTM) could be used to modify gene activity in the mouse embryo in utero...
  5. ncbi Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1371-88. 1998
    The finding of a decrease in contralateral breast cancer incidence following tamoxifen administration for adjuvant therapy led to the concept that the drug might play a role in breast cancer prevention...
  6. pmc MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
    Tyler E Miller
    Department of Molecular and Cellular Biochemistry, College of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 283:29897-903. 2008
    We explored the role of microRNAs (miRNAs) in acquiring resistance to tamoxifen, a drug successfully used to treat women with estrogen receptor-positive breast cancer...
  7. ncbi Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    J Clin Oncol 30:2718-24. 2012
    ..This analysis evaluated efficacy and safety of everolimus in combination with tamoxifen in patients with mBC resistant to aromatase inhibitors (AIs).
  8. ncbi Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse
    Shigemi Hayashi
    Department of Molecular and Cellular Biology, Harvard University, 16 Divinity Avenue, Cambridge, Massachusetts 02138, USA
    Dev Biol 244:305-18. 2002
    ..Cre and a mutated form of the ligand binding domain of the estrogen receptor (Cre-ER) that renders Cre activity tamoxifen (TM) inducible, allowing for conditional modification of gene activity in the mammalian neural tube in utero...
  9. ncbi Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 28:509-18. 2010
    To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2).
  10. ncbi American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 28:3784-96. 2010
    ..To develop evidence-based guidelines, based on a systematic review, for endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer...
  11. ncbi Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
    JAMA 295:2727-41. 2006
    b>Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis.
  12. pmc A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 16:5222-32. 2010
    ..IHC), and gene expression models of prognosis applicable to formalin-fixed, paraffin-embedded blocks in a large series of estrogen receptor (ER)-positive breast cancers from patients uniformly treated with adjuvant tamoxifen.
  13. ncbi Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
    A Ward
    Division of Molecular Genome Analysis, German Cancer Research Center DKFZ, Heidelberg, Germany
    Oncogene 32:1173-82. 2013
    ..It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies...
  14. pmc Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal
    Yuanzhi Lu
    Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 286:42292-302. 2011
    We have shown earlier that miR-221 and -222 are up-regulated in tamoxifen-resistant MCF-7 (OHT(R)) cells and Her2-positive human breast tumors when compared with Her2 negative tumors...
  15. pmc MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer
    Jian Jun Zhao
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Biol Chem 283:31079-86. 2008
    ..Notably, miR-221- and/or miR-222-transfected MCF-7 and T47D cells became resistant to tamoxifen compared with vector-treated cells...
  16. ncbi The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
    A K Shiau
    Howard Hughes Medical Institute and the Department of Biochemistry and Biophysics, University of California at San Francisco, 94143 0448, USA
    Cell 95:927-37. 1998
    ..These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation...
  17. pmc The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin
    V Vasioukhin
    Howard Hughes Medical Institute, Department of Molecular Genetics and Cell Biology, University of Chicago, Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 96:8551-6. 1999
    ..We have generated transgenic mice expressing Cre and a fusion protein between Cre recombinase and the tamoxifen responsive hormone-binding domain of the estrogen receptor (CreER(tam)) under the control of the human keratin ..
  18. ncbi Mechanisms of tamoxifen-induced apoptosis
    S Mandlekar
    Department of Drug Metabolism and Pharmacokinetics, DuPont Pharmaceuticals Company, Newark, DE 19711, USA
    Apoptosis 6:469-77. 2001
    b>Tamoxifen (TAM) has been used in the treatment of breast cancer for over a decade. The observed clinical efficacy of TAM has been attributed to both growth arrest and induction of apoptosis within the breast cancer cells...
  19. ncbi Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004
    Patients receiving adjuvant tamoxifen whose tumors express high levels of both HER2/neu (HER2) and the estrogen receptor (ER) coactivator AIB1 often develop tamoxifen resistance...
  20. pmc Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients
    Dawn L Hershman
    Mailman School of Public Health, Columbia University Medical Center, 161 Fort Washington Ave, New York, NY 10032, USA
    J Clin Oncol 28:4120-8. 2010
    ..We investigated the rates and predictors of early discontinuation and nonadherence to hormonal therapy in patients enrolled in Kaiser Permanente of Northern California health system...
  21. pmc Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University Medical Center, 161 Fort Washington Avenue, 10 1068, New York, NY 10032, USA
    Breast Cancer Res Treat 126:529-37. 2011
    ..Both early discontinuation and non-adherence to HT were common and associated with increased mortality. Interventions to improve continuation of and adherence to HT may be critical to improve BC survival...
  22. ncbi Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
    R Paridaens
    Universitair Ziekenhuis, Gasthuisberg, Leuven, Belgium
    Ann Oncol 14:1391-8. 2003
    ..We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women...
  23. pmc Preparation of hippurate-zinc layered hydroxide nanohybrid and its synergistic effect with tamoxifen on HepG2 cell lines
    Samer Hasan Hussein Al Ali
    Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia
    Int J Nanomedicine 6:3099-111. 2011
    ..A new simple preparation method for a hippurate-intercalated zinc-layered hydroxide (ZLH) nanohybrid has been established, which does not need an anion-exchange procedure to intercalate the hippurate anion into ZLH interlayers...
  24. pmc CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
    Meredith M Regan
    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Natl Cancer Inst 104:441-51. 2012
    Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer...
  25. pmc A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
    P N Munster
    Division of Hematology and Oncology, University of California, San Francisco, 1600 Divisadero, Rm A719 Box 1711, San Francisco, CA 94143, USA
    Br J Cancer 104:1828-35. 2011
    ..Preclinically, HDAC inhibitors can reverse tamoxifen/aromatase inhibitor resistance in hormone receptor-positive breast cancer...
  26. ncbi Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment
    Silvana Borges
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Pharmacol Ther 80:61-74. 2006
    N-Desmethyltamoxifen (NDM), a major primary metabolite of tamoxifen, is hydroxylated by cytochrome P450 (CYP) 2D6 to yield endoxifen...
  27. ncbi Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance
    R A Campbell
    Department of Surgery, Indiana University School of Medicine, Indianapolis 46202, USA
    J Biol Chem 276:9817-24. 2001
    ..Anti-estrogens such as tamoxifen inhibit the growth of ER-positive breast cancers by reducing the expression of estrogen-regulated genes...
  28. ncbi Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
    Jack Cuzick
    Cancer Research UK, Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary School of Medicine and Dentistry, University of London, London, UK
    Lancet Oncol 11:1135-41. 2010
    The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal ..
  29. pmc Equol enhances tamoxifen's anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells
    Christiana Charalambous
    Department of Biological Sciences, University of Cyprus, 75 Kallipoleos Str, PO Box 20537, Lefkosia 1678, Cyprus
    BMC Cancer 13:238. 2013
    ..Since the majority of estrogen receptor positive breast cancer patients are treated with tamoxifen, the basic objective of this study is to determine whether equol enhances tamoxifen's anti-tumor effect, and to ..
  30. ncbi A practical summary of site-specific recombination, conditional mutagenesis, and tamoxifen induction of CreERT2
    Konstantinos Anastassiadis
    Center for Regenerative Therapy, Technische Universitaet Dresden, Dresden, Germany
    Methods Enzymol 477:109-23. 2010
    ..Cre recombinase is vital for conditional mutagenesis, including for temporal mutagenesis via tamoxifen induction of recombinase-estrogen receptor fusion proteins...
  31. pmc Antifibrotic effect of tamoxifen in a model of progressive renal disease
    Humberto Delle
    Laboratory of Cellular, Genetic, and Molecular Nephrology, University of Sao Paulo, Av Dr Arnaldo, 455, 4th Floor, Lab 4304, Sao Paulo, CEP 01246 903, Brazil
    J Am Soc Nephrol 23:37-48. 2012
    b>Tamoxifen, a selective estrogen receptor modulator, has antifibrotic properties; however, whether it can attenuate renal fibrosis is unknown...
  32. pmc Tamoxifen-Induced Cre-loxP Recombination Is Prolonged in Pancreatic Islets of Adult Mice
    Rachel B Reinert
    Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
    PLoS ONE 7:e33529. 2012
    b>Tamoxifen (Tm)-inducible Cre recombinases are widely used to perform gene inactivation and lineage tracing studies in mice...
  33. pmc Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
    Joanne S L Lim
    Laboratory of Clinical Pharmacology, Division of Medical Sciences, Humphrey Oei Institute of Cancer Research, National Cancer Centre, Singapore
    Br J Clin Pharmacol 71:737-50. 2011
    To investigate the impact of genetic polymorphisms in CYP2D6, CYP3A5, CYP2C9 and CYP2C19 on the pharmacokinetics of tamoxifen and its metabolites in Asian breast cancer patients.
  34. ncbi Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen
    Aiping Zheng
    Institute of Biomedicine, Department of Anatomy, University of Turku, Tykistokatu 6A, 20520 Turku, Finland
    Endocrinology 148:2764-77. 2007
    b>Tamoxifen (Tam) is widely used in chemotherapy of breast cancer. It inhibits proliferation and induces apoptosis of breast cancer cells by estrogen receptor (ER)-dependent modulation of gene expression...
  35. ncbi Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
    ..of Ki67 in tumor biopsy samples taken before and after 2 weeks of presurgical treatment with anastrozole or tamoxifen or the combination of anastrozole plus tamoxifen in 158 patients with hormone receptor-positive primary disease...
  36. ncbi Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
    Janice M Knowlden
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, United Kingdom
    Endocrinology 144:1032-44. 2003
    ..We have developed a tamoxifen-resistant (TAM-R) MCF-7 breast cancer cell line to investigate the mechanisms behind this condition...
  37. ncbi Molecular determinants for the tissue specificity of SERMs
    Yongfeng Shang
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Science 295:2465-8. 2002
    ..The therapeutic effectiveness of SERMs such as tamoxifen and raloxifene in breast cancer depends on their antiestrogenic activity...
  38. ncbi Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein
    D S Sohal
    Department of Pediatrics, University of Cincinnati, Children s Hospital Medical Center, Division of Molecular Cardiovascular Biology, Cincinnati, Ohio, USA
    Circ Res 89:20-5. 2001
    ..Here we generated transgenic mice expressing a tamoxifen-inducible Cre recombinase protein fused to two mutant estrogen-receptor ligand-binding domains (MerCreMer) under ..
  39. ncbi Effect of screening and adjuvant therapy on mortality from breast cancer
    Donald A Berry
    Department of Biostatistics and Applied Mathematics, M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 353:1784-92. 2005
    ..We used modeling techniques to assess the relative and absolute contributions of screening mammography and adjuvant treatment to the reduction in breast-cancer mortality in the United States from 1975 to 2000...
  40. ncbi Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
    Michael D Johnson
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Breast Cancer Res Treat 85:151-9. 2004
    The antiestrogen tamoxifen is extensively metabolized in patients to form a series of compounds with altered affinity for estrogen receptors (ERs), the primary target of this drug...
  41. pmc Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
    Robert J Paridaens
    University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Oncol 26:4883-90. 2008
    ..clinical trial was designed to evaluate the efficacy and safety of the steroidal aromatase inactivator exemestane versus the antiestrogen tamoxifen as first-line treatment for metastatic breast cancer (MBC) in postmenopausal women.
  42. ncbi Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
    Sandra E Ghayad
    Universite de Lyon, France
    Int J Cancer 126:545-62. 2010
    ..that two ER+ human breast carcinoma cell lines derived from MCF-7 (MVLN cells) that have acquired under OH-Tamoxifen selection two distinct phenotypes of endocrine resistance both displayed constitutive activation of the PI3K/Akt ..
  43. ncbi Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
    Ann H Partridge
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D1210, Boston, MA 02215, USA
    J Clin Oncol 21:602-6. 2003
    Although clinical trials have clearly demonstrated the benefits of tamoxifen in women with primary breast cancer, little is known about how this drug is actually used in the general population...
  44. pmc Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
    ..We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy...
  45. pmc Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements
    Christoph Lepper
    Department of Embryology, Carnegie Institution, 3520 San Martin Drive, Baltimore, Maryland 21218, USA
    Nature 460:627-31. 2009
    ....
  46. ncbi Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation
    Stephen Hiscox
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom
    Int J Cancer 118:290-301. 2006
    ..an aggressive phenotype, we investigated the integrity of this protein complex in our breast cancer model of tamoxifen resistance...
  47. pmc Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
    C Kent Osborne
    Lester and Sue Smith Breast Center and Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 17:1147-59. 2011
    Increased growth factor signaling may contribute to tamoxifen resistance...
  48. ncbi Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth
    Gérard Maillot
    Institut National de la Sante et de la Recherche Medicale U563, Institut Claudius Regaud, and universite de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France
    Cancer Res 69:8332-40. 2009
    ....
  49. ncbi Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters
    Kazuma Kiyotani
    Laboratory for Pharmacogenetics, RIKEN Center for Genomic Medicine, Yokohama, Japan
    Drug Metab Pharmacokinet 27:122-31. 2012
    b>Tamoxifen has been widely used for the prevention of recurrence in patients with hormone receptor-positive breast cancer...
  50. ncbi Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
    ..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed...
  51. ncbi Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study
    J Sven D Mieog
    Department of Surgery, Leiden University Medical Center, Leiden, Netherlands
    Lancet Oncol 13:420-32. 2012
    Aromatase inhibitors are more effective than is tamoxifen in prevention of breast-cancer recurrence, but at the expense of increased musculoskeletal side-effects, such as carpal tunnel syndrome...
  52. pmc EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
    P Dubsky
    Departments of Surgery, Medical University Vienna, A 1090 Vienna, Austria
    Ann Oncol 24:640-7. 2013
    ..In this study, the clinical relevance of EPclin in relation to well-established clinical guidelines is assessed...
  53. ncbi G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer
    Atanas Ignatov
    Department of Obstetrics and Gynecology, Otto von Guericke University, G Hauptmann Str 35, 39108 Magdeburg, Germany
    Breast Cancer Res Treat 128:457-66. 2011
    ..have shown that the new G-protein-coupled estrogen receptor GPR30 plays an important role in the development of tamoxifen resistance in vitro...
  54. pmc Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study
    Maria B Lyng
    Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
    PLoS ONE 7:e36170. 2012
    ..miRNAs) have been suggested as promising biomarkers and we here evaluated whether a miRNA profile could be identified, sub-grouping ER+ breast cancer patients treated with adjuvant Tamoxifen with regards to probability of recurrence.
  55. pmc The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway
    Kideok Jin
    Breast Cancer Program, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Proc Natl Acad Sci U S A 109:2736-41. 2012
    Multiple factors including long-term treatment with tamoxifen are involved in the development of selective estrogen receptor (ER) modulator resistance in ERα-positive breast cancer...
  56. pmc Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors
    H Irene Su
    Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer 116:592-9. 2010
    ....
  57. pmc Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway
    Bhuvaneswari Ramaswamy
    Division of Medical Oncology, Department of Molecular and Cellular Biochemistry, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    Cancer Res 72:5048-59. 2012
    ..show that noncanonical Hedgehog (Hh) signaling is an alternative growth promoting mechanism that is activated in tamoxifen-resistant tumors...
  58. ncbi Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state
    Kelly A Green
    Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    Nat Rev Cancer 7:713-22. 2007
    ..specific promoter regions, we now have an improved understanding of the nature of these interactions and are better placed to relate these with ER activity and potentially with the activity of breast cancer drugs, including tamoxifen.
  59. pmc Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer
    Chungyeul Kim
    National Surgical Adjuvant Breast and Bowel Project, Division of Pathology, 1307 Federal St, Pittsburgh, PA 15212, USA
    J Clin Oncol 29:4160-7. 2011
    Several mechanisms have been proposed to explain tamoxifen resistance of estrogen receptor (ER) -positive tumors, but a clinically useful explanation for such resistance has not been described...
  60. ncbi The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
    Ron H N van Schaik
    Erasmus MC Rotterdam, The Netherlands
    Pharmacogenomics 12:1137-46. 2011
    b>Tamoxifen is metabolized by cytochrome P450s, with an important role for CYP2D6. Recently, we demonstrated in 80 patients that CYP2C19*2 is associated with increased survival in breast cancer patients using tamoxifen...
  61. pmc Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance
    A Bergamaschi
    Department of Molecular and Integrative Physiology, University of Illinois and College of Medicine at Urbana Champaign, Urbana, IL, USA
    Oncogene 31:39-47. 2012
    ..endocrine therapies, but often develop resistance during treatment with selective ER modulators (SERMs) such as tamoxifen. We have reported that the 14-3-3 family member and conserved protein, 14-3-3ζ, is upregulated by tamoxifen and ..
  62. ncbi Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6
    Zeruesenay Desta
    Indiana University School of Medicine, Department of Medicine Division of Clinical Pharmacology, 1001 West 10th Street, WD Myers Bldg, W7123, Indianapolis, IN 46202, USA
    J Pharmacol Exp Ther 310:1062-75. 2004
    ..experiments in expressed human cytochromes P450 (P450s) to identify primary and secondary metabolic routes of tamoxifen (TAM) and the P450s catalyzing these reactions at therapeutically relevant concentrations...
  63. ncbi Identification of novel ER-alpha target genes in breast cancer cells: gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen
    Andrea Romano
    GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands
    Mol Cell Endocrinol 314:90-100. 2010
    b>Tamoxifen and 17beta-estradiol are capable of up-regulating the expression of some genes and down-regulate the expression of others simultaneously in the same cell...
  64. pmc Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
    Diana M Cittelly
    Department of Pathology, University of Colorado Denver, School of Medicine, Aurora, Colorado 80045, USA
    Mol Cancer 9:317. 2010
    Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress HER2...
  65. pmc Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
    Meredith M Regan
    International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Lancet Oncol 12:1101-8. 2011
    ..Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up...
  66. ncbi Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis
    Huijian Wu
    Department of Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100083, China
    Nature 438:981-7. 2005
    b>Tamoxifen, a selective oestrogen receptor modulator, has been used in the treatment of all stages of hormone-responsive breast cancer...
  67. ncbi Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    Vered Stearns
    The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Natl Cancer Inst 95:1758-64. 2003
    b>Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes...
  68. ncbi Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    M Carolina Gutierrez
    Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:2469-76. 2005
    To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance.
  69. ncbi Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K
    M Sun
    Department of Pathology and Programs of Molecular Oncology and Drug Discovery, University of South Florida College of Medicine and H Lee Moffitt Cancer Center, Tampa, Florida 33612, USA
    Cancer Res 61:5985-91. 2001
    ..However, AKT2-induced ERalpha activity was not inhibited by tamoxifen but was completely abolished by ICI 164,384, implicating that AKT2-activated ERalpha contributes to tamoxifen ..
  70. pmc CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients
    James M Rae
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    J Natl Cancer Inst 104:452-60. 2012
    Adjuvant tamoxifen therapy substantially decreases the risk of recurrence and mortality in women with hormone (estrogen and/or progesterone) receptor-positive breast cancer...
  71. ncbi Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients
    Caroline Holm
    Division of Pathology, Department of Laboratory Medicine, Lund University, Malmo, Sweden
    J Natl Cancer Inst 98:671-80. 2006
    ..Here we studied associations between Pak1 expression and subcellular localization in tumor cells and tamoxifen resistance.
  72. ncbi Early discontinuation of tamoxifen: a lesson for oncologists
    Thomas I Barron
    Department of Pharmacology and Therapeutics, Trinity College Dublin, Trinity Centre for Health Sciences, St James s Hospital, Dublin, Ireland
    Cancer 109:832-9. 2007
    Five years of treatment provides the optimum duration of tamoxifen therapy for the prevention of breast cancer recurrence and mortality...
  73. ncbi Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study
    Mitch Dowsett
    Royal Marsden Hospital, Wolfson Institute for Preventive Medicine, Queen Mary University of London London
    J Clin Oncol 28:1829-34. 2010
    ..whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the tamoxifen and anastrozole arms of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial...
  74. ncbi Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen
    Young Chai Lim
    Division of Clinical Pharmacology, Indiana University School of Medicine, 1001 West 10th Street, WD Myers Bldg, W7123, Indianapolis, Indiana 46202, USA
    Cancer Chemother Pharmacol 55:471-8. 2005
    b>Tamoxifen is an effective drug for the treatment and prevention of breast cancer. It is extensively metabolized by the human cytochrome P450 enzyme system into several metabolites...
  75. pmc Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
    Antoni Hurtado
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Nature 456:663-6. 2008
    ..Here we show that oestrogen-ER and tamoxifen-ER complexes directly repress ERBB2 transcription by means of a cis-regulatory element within the ERBB2 gene in ..
  76. pmc Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
    C McCowan
    Division of Community Health Sciences, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee DD2 4BF, UK
    Br J Cancer 99:1763-8. 2008
    Increasing duration of tamoxifen therapy improves survival in women with breast cancer but the impact of adherence to tamoxifen on mortality is unclear...
  77. ncbi A noninvasive genetic/pharmacologic strategy for visualizing cell morphology and clonal relationships in the mouse
    Tudor C Badea
    Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Neurosci 23:2314-22. 2003
    ..Histochemical visualization of alkaline phosphatase activity reveals neuronal morphology with strong and uniform labeling of all processes...
  78. ncbi Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
    M Overgaard
    Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
    Lancet 353:1641-8. 1999
    ..However, whether the same benefits apply also in postmenopausal women treated with adjuvant tamoxifen for similar high-risk cancer is unclear...
  79. pmc Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
    G Pérez-Tenorio
    Department of Biomedicine and Surgery, Division of Oncology, Clinical Research Center, Faculty of Health Sciences, Linkoping University, SE 581 85 Linkoping, Sweden
    Br J Cancer 86:540-5. 2002
    ..This study comprised 93 patients, aged <50 who were treated with tamoxifen and/or goserelin. We found that pAkt was associated with lower S-phase fraction (P=0...
  80. ncbi Mechanisms of tamoxifen resistance
    Alistair Ring
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK
    Endocr Relat Cancer 11:643-58. 2004
    The anti-oestrogen tamoxifen is the most commonly used treatment for patients with oestrogen-receptor (ER)-positive breast cancer...
  81. ncbi CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen
    Rikje Ruiter
    Department of Epidemiology, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Pharmacogenomics 11:1367-75. 2010
    Variant alleles of the CYP2C19 gene were recently associated with survival in breast cancer patients on tamoxifen therapy. CYP2C19 is one of the enzymes involved in the metabolism of tamoxifen into active metabolites...
  82. pmc Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
    Jack Cuzick
    Cancer Research UK, Centre for Epidemiology, Mathematics, and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary School of Medicine and Dentistry, University of London, London, UK
    Lancet Oncol 12:21-9. 2011
    ..that radiotherapy reduced new breast events of ipsilateral invasive and ductal carcinoma in situ (DCIS) compared with no radiotherapy, but no significant effects were noted with tamoxifen. Here, we report long-term results of this trial.
  83. ncbi Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study
    Mario R Korte
    Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands
    Nephrol Dial Transplant 26:691-7. 2011
    ..clear consensus on the treatment of EPS, but anecdotal reports indicate improvement in EPS patients treated with tamoxifen. At present, there is no evidence for the effect of tamoxifen treatment in EPS patients...
  84. pmc Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
    Jennifer Gjerde
    Hormone Laboratory, Haukeland University Hospital, Bergen, N 5021, Norway
    BMC Cancer 10:313. 2010
    ..enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam, endoxifen)...
  85. ncbi Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment
    Dedra H Fagan
    Masonic Cancer Center, and Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Cancer Res 72:3372-80. 2012
    ..In this study, we examined the effectiveness of IGF1R inhibitors in vitro by generating tamoxifen-resistant (TamR) cells...
  86. ncbi Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue
    Line L Haugan Moi
    Institute of Medicine, University of Bergen, Hormone Laboratory, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 16:2176-86. 2010
    Nuclear receptor coactivator expression and activity may partly explain the complex agonist/antagonist effects of tamoxifen at clinical level...
  87. ncbi Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles
    Harikrishna Devalapally
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA
    Clin Cancer Res 14:3193-203. 2008
    ..threshold in multidrug-resistant ovarian adenocarcinoma, we have examined the efficacy and preliminary safety of tamoxifen coadministration with paclitaxel in biodegradable poly(ethylene oxide)-modified poly(epsilon-caprolactone) (PEO-..
  88. ncbi Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
    Cornelis J H Van De Velde
    Leiden University Medical Centre, Leiden, Netherlands
    Lancet 377:321-31. 2011
    Aromatase inhibitors improved disease-free survival compared with tamoxifen when given as an initial adjuvant treatment or after 2-3 years of tamoxifen to postmenopausal women with hormone-receptor-positive breast cancer...
  89. ncbi Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma
    T E Mürdter
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 89:708-17. 2011
    The therapeutic effect of tamoxifen depends on active metabolites, e.g., cytochrome P450 2D6 (CYP2D6) mediated formation of endoxifen...
  90. ncbi The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy
    Yi Zhang
    Veridex LLC, Johnson and Johnson Company, San Diego, CA, USA
    Breast Cancer Res Treat 116:303-9. 2009
    To assess the benefit from adjuvant systemic tamoxifen therapy in breast cancer risk groups identified by the previously established prognostic 76-gene signature.
  91. pmc Estrogen and tamoxifen reverse manganese-induced glutamate transporter impairment in astrocytes
    Eun Sook Y Lee
    Department of Neurology, Meharry Medical College, Nashville, Tennessee 37208, USA
    J Neurochem 110:530-44. 2009
    ..Parkinson's disease and Alzheimer's disease, and some selective estrogen receptor modulators, including tamoxifen (TX), also possess neuroprotective properties...
  92. pmc CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen
    Jean E Abraham
    Department of Oncology, Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 12:R64. 2010
    b>Tamoxifen is one of the most effective adjuvant breast cancer therapies available. Its metabolism involves the phase I enzyme, cytochrome P4502D6 (CYP2D6), encoded by the highly polymorphic CYP2D6 gene...
  93. pmc American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
    Kala Visvanathan
    Cancer Policy and Clinical Affairs, 2318 Mill Rd, Suite 800, Alexandria, VA 22314, USA
    J Clin Oncol 27:3235-58. 2009
    ..Results Seventeen articles met inclusion criteria. In premenopausal women, tamoxifen for 5 years reduces the risk of BC for at least 10 years, particularly estrogen receptor (ER) -positive invasive ..
  94. ncbi Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats
    Dai Shi Tian
    Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    J Neurochem 109:1658-67. 2009
    b>Tamoxifen has been found to be neuroprotective in both transient and permanent experimental ischemic stroke...
  95. pmc Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
    M Rabaglio
    IBCSG Coordinating Center and Inselspital, Bern, Switzerland
    Ann Oncol 20:1489-98. 2009
    To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial.
  96. ncbi Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor
    Selma Masri
    Department of Surgical Research, Division of Information Sciences, Beckman Research Institute of the City of Hope, Duarte, California, USA
    Cancer Res 68:4910-8. 2008
    Acquired resistance to either tamoxifen or aromatase inhibitors (AI) develops after prolonged treatment in a majority of hormone-responsive breast cancers...
  97. ncbi Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure
    Igor P Pogribny
    Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, United States
    Mutat Res 619:30-7. 2007
    ..Here we report that exposure of Fisher 344 rats to tamoxifen, a potent hepatocarcinogen in rats, for 24 weeks leads to substantial changes in the expression of miRNA genes ..
  98. pmc Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors
    Diana M Cittelly
    Department of Pathology, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
    Carcinogenesis 31:2049-57. 2010
    b>Tamoxifen is the most commonly prescribed therapy for patients with estrogen receptor (ER)α-positive breast tumors...
  99. ncbi Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism
    J Gjerde
    The Hormone Laboratory, Haukeland University Hospital, N 5021 Bergen
    Ann Oncol 19:56-61. 2008
    b>Tamoxifen is hydroxylated by cytochrome P450 (CYP) 2D6 to the potent metabolites 4-hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam), which are both conjugated by sulphotransferase (SULT)1A1...
  100. pmc Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study
    William J Irvin
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 29:3232-9. 2011
    We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by genotype-guided tamoxifen dosing in patients with ..
  101. ncbi Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription
    Y Shang
    Boston, MA, USA
    Cell 103:843-52. 2000
    ..Cycles of ER complex assembly are followed by transcription. In contrast, the anti-estrogen tamoxifen (TAM) recruits corepressors but not coactivators...

Research Grants78

  1. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2006
    ..in the eye and visual system as a result of estrogen-receptor action and to elucidate the effects of 2 SERMS, tamoxifen and raloxifene, as functions of their durations of use...
  2. Transcription factors regulating sensory gene expression and pain pathways
    Eric E Turner; Fiscal Year: 2011
    ..To test this hypothesis we will induce excision of conditional alleles of Islet1 and Brn3a in adult mice using tamoxifen-induced Cre-recombinase...
  3. Development of VN/14-1 and Related Analogs for Breast Cancer Therapy
    VINCENT COLLINS OFUKA NJAR; Fiscal Year: 2013
    ..e., tumors that are resistant to mainstay breast cancer therapies such as tamoxifen and aromatase inhibitors) breast cancer xenograft models...
  4. Transgenesis and Xenotransplantation
    Jorge A Piedrahita; Fiscal Year: 2013
    ..Aim 3a will focus on generation of a transgenic swine carrying Cre-ERT2, a tamoxifen inducible Cre, driven by a liver-specific promoter...
  5. Metabolic mechanisms of antiestrogen resistance in breast cancer
    UBALDO EMILIO MARTINEZ OUTSCHOORN; Fiscal Year: 2013
    ..will be measured by quantifying apoptosis and proliferation of the breast cancer cells after treatment with tamoxifen and fulvestrant...
  6. Regulation of Islet Beta-Cell Function via Islet-Derived VGF Peptides
    SAMUEL BRANDON STEPHENS; Fiscal Year: 2013
    ..a novel reagent -a conditional [unreadable]-cell specific deletion of VGF using a floxed VGF allele and a tamoxifen inducible, [unreadable]-cell specific Cre driver, MIP-Cre/ERT...
  7. P38 MAP KINASE SIGNALING IN SKIN
    Tatiana Efimova; Fiscal Year: 2013
    ..of p384 gene in a temporally regulated fashion, by means of crossing p384flox mice to transgenic mice in which a tamoxifen-regulated CreERT recombinase is expressed under the control of keratinocyte-specific human keratin 14 promoter...
  8. Inducible Macrophage Specific Gene Expression in Diseases
    JEANINE M D apos ARMIENTO; Fiscal Year: 2010
    ..After its induction with tamoxifen, Cre will cleave any "floxed" gene in macrophages...
  9. Endocrine Targets for Prevention of Lung Cancer
    Robert M Bigsby; Fiscal Year: 2012
    ..Our preliminary observations indicate that the widely used antiestrogens, tamoxifen and fulvestrant, behave as agonists, promoting tumorigenesis in the mouse lung cancer model;these two ..
  10. Mechanism and therapy for arteriovenous malformation
    Suk Paul Oh; Fiscal Year: 2013
    ..We will establish pulmonary ECs from tamoxifen-inducible Alk1-conditional knockout mice...
  11. Inducible recombination and gene expression in specific neurotransmitter systems
    Steven A Thomas; Fiscal Year: 2012
    ..The main approach for achieving this will be the neurotransmitter-specific expression of the tamoxifen-inducible Cre fusion protein, CreERT2, that is fused to a modified estrogen receptor ligand-binding domain (ERT2)..
  12. RCT of exercise on aromatase inhibitor side effects in breast cancer survivors
    Melinda L Irwin; Fiscal Year: 2012
    ..Although 5 years of tamoxifen had long been the standard adjuvant hormonal therapy for women with early- stage, hormone receptor-positive ..
  13. Lifestyle and Molecular Factors of Bone Health in Breast Cancer Survivors
    Song Yao; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Aromatase inhibitors (AIs) have been rapidly replacing tamoxifen (TAM) as first-line adjuvant hormonal therapy for postmenopausal women diagnosed with hormone receptor (HR)-positive, early-stage ..
  14. REGULATION OF ATROPHY-INDUCED PROGENITOR CELLS IN THE GASTRIC CORPUS
    Jason C Mills; Fiscal Year: 2013
    ..Preliminary data show that the selective estrogen receptor modulator tamoxifen causes ablation of nearly all parietal cells, the acid-secreting lineage, in the mouse stomach within 3 days...
  15. Astrocytes Play a Critical Role in the Pathology of EAE
    JOHN ROLAND BETHEA; Fiscal Year: 2013
    ..Michael Karin. The second mouse line (GFAPCreERT2xffIKKb) is obtained by breeding a tamoxifen inducible GFAP-Cre line (CreERT2) developed in Dr. McCarthy's lab to the same floxed (f/f) IKKb line...
  16. Chemoprevention of Tamoxifen-induced Endometrial cancer by black cohosh and red c
    BIRGIT MARIA DIETZ; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Chemoprevention of Tamoxifen-induced Endometrial cancer by black cohosh and red clover Breast cancer is the most common cancer in women...
  17. Estrogen receptor, p38 MAPKs and topo IIa in breast cancer
    Guan Chen; Fiscal Year: 2013
    ..Although patients with ER+ breast cancer (about 70% of all patients) benefit from hormonal therapy such as tamoxifen, there have been no valid therapeutic targets for ER- breast cancers that account for about 30% of patients...
  18. Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
    Scott T Eblen; Fiscal Year: 2013
    ..Over-expression of the splicing factor SPF45 in ovarian cancer cells results in a tamoxifen sensitive drug-resistant phenotype. The mechanism of SPF45-mediated drug resistance is unknown...
  19. Mechanisms and Functions of Bimodally Targeted Cytochrome P450s to Mitochondria
    Narayan G Avadhani; Fiscal Year: 2012
    ..2) The role of mt-CYP2D6 in the metabolism of drugs such as bufuralol, tamoxifen, chlorpromazine and toxicants such as MPTP will be investigated...
  20. Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients
    Dawn Hershman; Fiscal Year: 2013
    Third generation aromatase inhibitors have been shown to be superior to tamoxifen in improving disease free survival, decreasing distant and local recurrence rates and decreasing incidence of contra-lateral breast cancer in women with ..
  21. Post-Developmental Adipocyte Autophagy in Control of Insulin-Glucose Homeostasis
    Timothy E Graham; Fiscal Year: 2013
    ..so that autophagy can be turned off in adulthood, after the developmental period of intense adipogenesis, via a tamoxifen- inducible genetic impairment...
  22. CRP, eNOS and Endothelial Dysfunction
    Philip W Shaul; Fiscal Year: 2010
    ..receptor will be deleted in endothelium by crossing floxed Fc?RIIB mice (Fc?RIIBflox/flox) with mice expressing tamoxifen-inducible Cre-recombinase under the regulation of the vascular endothelial cadherin promoter (VECad-Cre-ERT2)...
  23. A novel therapy for HER2 positive hormone refractory breast cancer
    Anne W Hamburger; Fiscal Year: 2010
    ..demonstrate that ecoptic expression of EBP1 increases sensitivity of breast cancer cells to the antiestrogen tamoxifen. Further, depletion of EBP1 protein by shRNA or inactivation of EBP1 by phosphorylation by PAK1, a kinase ..
  24. Elucidating the in vivo Role of the p53 Apoptosis-Specific Target Gene Siva
    Jeanine L Frey; Fiscal Year: 2013
    ..knockout mice (Sivafl/fl) that we generated with Rosa-26-Cre-ER mice to ubiquitously delete Siva through tamoxifen treatment and assess the effect of Siva-deficiency on apoptosis levels in radiosensitive tissues known to ..
  25. Targeted epigenetic therapy of triple-negative breast cancer
    Samuel Waxman; Fiscal Year: 2013
    ..Moreover, in the human triple- negative cell lines the responsiveness to estrogen, tamoxifen and RAR agonists is restored...
  26. REGULATION OF STROMAL WOUND HEALING BY GROWTH FACTORS
    GREGORY SCOTT SCHULTZ; Fiscal Year: 2012
    ..a new CTGF conditional knockout mouse strain that we will develop that stops synthesis of CTGF after exposure to tamoxifen (CTGFfloxed/floxed CreCAG-cre/Esr/+)...
  27. The Role of Kappa Opioid Receptor-induced Activation of Astrocytes in the Reinsta
    Charles Chavkin; Fiscal Year: 2009
    ..study, we propose to use transgenic GFAP-CreERT2 mice in which Crerecombinase expression is regulated both by a tamoxifen-inducible DNA recombinase variant and by the Glial acidic fibrillary protein (GFAP) promoter...
  28. Modulation of beta-cell PKA activity affects glucose homeostasis
    Barton Wicksteed; Fiscal Year: 2013
    ..In aims 1 and 2 PKA activity will be altered by administering tamoxifen at 10 weeks of age and the mice characterized during the 11th week...
  29. THE TEMPORAL AND SPATIAL REGULATION OF BONE ACQUISITION BY SERUM IGF-1
    Shoshana Yakar; Fiscal Year: 2012
    ..is expressed specifically in the liver under the anti-trypsin-11 promoter, and can be induced by a single tamoxifen injection that does not otherwise affect the skeleton...
  30. Cytochrome P4501B1 and basal liver PPARa activity
    COLIN ROBERT JEFCOATE; Fiscal Year: 2013
    ..Cre-targeting of Floxed Cyp1b1 will be activated through a tamoxifen-dependent promoter at selected times during development, in order to test whether this early expression ..
  31. Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles
    Lily Yang; Fiscal Year: 2013
    ..It is not a candidate for two common therapies for breast cancer: hormonal (tamoxifen) and Her-2 targeted (Herceptin) therapy...
  32. Investigation of the liver progenitor cell niche using CK19 lineage tracing
    EUGENE SCOTT SWENSON; Fiscal Year: 2011
    ..In the adult, CK19 is expressed by cholangiocytes, but not hepatocytes. I will use the tightly regulated, Tamoxifen-inducible CK19-CreERT transgenic mouse model to mark CK19-expressing cells at specific times during development, ..
  33. MicroRNA Signature of Tamoxifen Resistance in Breast Cancer
    Sarmila Majumder; Fiscal Year: 2010
    ..b>Tamoxifen (TAM) is the current standard adjuvant therapy in pre-menopausal women with hormone receptor positive breast ..
  34. Crosstalk between estrogen receptor and NFkB in target gene regulation
    Jonna Frasor; Fiscal Year: 2013
    ..activation of NF?B is associated with more aggressive estrogen receptor (ER) positive tumors, the development of tamoxifen resistance, and progression to estrogen-independent growth...
  35. Chemopreventative properties of Medicinal and Food plants of the Lumbee Tribe
    TRACIE LOCKLEAR; Fiscal Year: 2010
    ..2006). To date, only tamoxifen is FDA approved for the prevention of breast cancer in high risk individuals...
  36. Regulation of miRNA in breast cancer
    Carolyn M Klinge; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The selective estrogen receptor modulator (SERM) tamoxifen (TAM) is the most widely used endocrine therapy for the treatment and prevention of estrogen receptor alpha (ER1) positive breast cancer...
  37. Mechanisms of Anti-fungal Vaccine Immunity
    BRUCE STEVEN KLEIN; Fiscal Year: 2013
    ..By using mice to conditionally delete (with tamoxifen) MyD88 in only T cells, we will study when &how MyD88 intrinsically directs Tc17 cell development, and ..
  38. Non-genomic actions of estrogen in breast cancer
    Ellis R Levin; Fiscal Year: 2013
    ..These proteins could be therapeutic targets in breast cancer. In specific aim 2, we propose a novel basis for tamoxifen resistance involving ER? in mitochondria...
  39. Actions of Parathyroid Hormone (PTH)/PTH Related-Peptide Receptor in Osteocytes
    PAOLA DIVIETI PAJEVIC; Fiscal Year: 2013
    ..The 10Kb-DMP1 promoter, active specifically in osteocytes, will drive a Tamoxifen-inducible Cre expression in cells in which the PPR gene is flanked by lox-P sites...
  40. Regulation of miRNA expression in breast cancer cells
    CAROLYN KLINGE; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The selective estrogen receptor modulator (SERM) tamoxifen (TAM) is the most widely used endocrine therapy for the treatment and prevention of estrogen receptor alpha (ERalpha) positive breast cancer...
  41. Fliz1 regulation of GATA-3 in breast cancer
    Janice E Knepper; Fiscal Year: 2013
    ..3) Determine if Fliz-1 silencing results in increased sensitivity to tamoxifen in vivo and in vitro...
  42. Postnatal Serotonin Deficits in Behavioral Pathogenesis: A Novel Genetic Approach
    MEREDITH SORENSON WHITNEY; Fiscal Year: 2013
    ..We have generated mice that express a tamoxifen (TM)-inducible CreER, ePet:CreERT2ascend, in ascending 5-HT neurons, which project to forebrain circuitry ..
  43. Manipulation of Follicular Helper T Cells in Immunity and Autoimmunity
    Joseph Craft; Fiscal Year: 2013
    ..We propose to make a tamoxifen-inducible-Cre mouse in which Cre, fused with the estrogen receptor ERT2, will be expressed downstream of the ..
  44. CARP-1: A Potential Therapeutic Agent for Breast Cancer
    ARUN KUMAR RISHI; Fiscal Year: 2013
    ..CFM-4 also attenuates growth of tamoxifen (TAM) or adriamycin (ADR)-resistant HBC cells but does not suppress growth of the non-tumorigenic and ..
  45. Fractures, Heart Disease, and Stroke on Aromatase Inhibitors
    Nancy L Keating; Fiscal Year: 2010
    ..increase in non-breast cancer deaths in patients taking aromatase inhibitors compared to women on tamoxifen or placebo, suggesting that the drugs may impact the risk of death from other causes, such as cardiovascular ..
  46. Signal transduction mechanisms to myosin phosphatase
    James T Stull; Fiscal Year: 2013
    ..signaling to RLC phosphorylation? We will knock out MYPT1 in adult mice containing floxed MYPT1 alleles by tamoxifen-controlled Cre expression specifically in smooth muscle cells...
  47. Role of cofilin pathology in mouse models of cognitive impairment
    James R Bamburg; Fiscal Year: 2013
    ..Two of these will make a conditional mouse which expresses wild type cofilin until mice are given tamoxifen. In these mice tamoxifen activates expression of Cre recombinase, which will initiate the inactivation of the ..
  48. Prevalence of CD24 epigenetic silencing in breast tumors and ERalpha status
    Benny Abraham Kaipparettu; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: Project Narrative Endocrine therapy like Tamoxifen treatment remains important in premenopausal women with hormone receptor positive breast cancer as it work best ..
  49. Effect of Satellite Cell Ablation on the Aging Diaphragm
    Esther E Dupont-Versteegden; Fiscal Year: 2013
    ..of satellite cell ablation;we showed previously that >90% of satellite cells are ablated in response to tamoxifen treatment using this genetic model...
  50. Sensory cell fate specification in the inner ear
    Douglas J Epstein; Fiscal Year: 2012
    ..Using a tamoxifen inducible form of cre recombinase, expressed under the transcriptional control of a Wnt responsive Top promotor (..
  51. Epigenetic Regulation of Breast Cancer Progression by the Proto-oncogene PELP1
    MONICA MANN; Fiscal Year: 2013
    ..Endocrine therapies using tamoxifen and aromatase inhibitors substantially improve disease- free survival, however, initial or acquired resistance ..
  52. MOLECULAR PROBES FOR STEROID RECEPTORS
    John A Katzenellenbogen; Fiscal Year: 2012
    ..corepressors, the agonism of SERMs such as tamoxifen, and ligand regulation of the function of ERc_.ERI3 heterodimers...
  53. Environmental Enrichment and Neuronal Turnover in the Brain
    Flora M Vaccarino; Fiscal Year: 2010
    ..in which GFAP+ cells express a constitutively inactive Cre recombinase that can be transiently activated by a tamoxifen injection in vivo, allowing to genetically "mark" a time-specific cohort of astroglial cells with EGFP to follow ..
  54. Application of Evolutionary Principles to Maintain Cancer Control (PQ21)
    Robert A Gatenby; Fiscal Year: 2013
    ..authors propose to combine three chemotherapeutic strategies currently used in the clinic: (a) hormonal therapy (tamoxifen and aromatase inhibitors), (b) targeted therapy (herceptin), and (c) standard chemotherapy (doxorubicin and ..
  55. ABC: Antidepressants and Breast Cancer Pharmacoepidemiology
    Reina Haque; Fiscal Year: 2012
    ..Cancer Treatment Pharmacoepidemiology Tens of thousands of American women with breast cancer are taking tamoxifen to reduce their chances of developing a recurrence or second primary breast cancer...
  56. A Hypersensitive ER alpha Mutant in Breast Cancer Hormone Resistance
    Suzanne Aw Fuqua; Fiscal Year: 2012
    ..Furthermore, the mutant ER? causes the antiestrogen tamoxifen (Tam) to act as an agonist rather than an antagonist, which would lead to Tam resistance in tumors...
  57. A Neoadjuvant Trial of Anastrazole and A Novel SRC Inhibitor, AZD0530, for LABC
    JOYCE MARIE contact SLINGERLAND; Fiscal Year: 2010
    Estrogen receptor 1 (ER) is expressed in 70% of new breast cancers but de novo and acquired resistance to tamoxifen or aromatase inhibitors (AI) limit their efficacy...
  58. Atlanta Regional Community Clinical Oncology Program (ARCCOP)
    Thomas E Seay; Fiscal Year: 2012
    ..The ARCCOP is a clinical site for the Study of Tamoxifen and Raloxefene (STAR) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT) for breast and prostate ..
  59. The use of genetic models to define the role of beta-catenin in post-natal growth
    REGIS J O'KEEFE; Fiscal Year: 2011
    ..Preliminary data establish that delivery of tamoxifen to Col2a1-Cre+/-ERT2 transgenic mice results in tissue specific gene recombination...
  60. The role of the mTOR signaling pathway in ER-positive breast cancer
    MARINA KAUFMAN HOLZ; Fiscal Year: 2013
    ..ER-positive breast cancers can be targeted therapeutically by antiestrogens (such as tamoxifen) or aromatase inhibitors (AIs)...
  61. Mass spectrometry to decode PTM patterns and enhance the Biomarker utility of ER
    Christopher Benz; Fiscal Year: 2013
    ..for MRM/MS analysis are powered to: i) validate our Aim 1 derived ER PTM profile associating with cell line tamoxifen responsiveness, and ii) independently derive and validate a tumor ER PTM profile associating with clinical ..
  62. FETAL AND POSTNATAL DEVELOPMENT OF VISUAL CONNECTIONS
    Carla J Shatz; Fiscal Year: 2013
    ..PirB flox/flox) has been made, allowing acute temporal and cell-type disruption of PirB by crossing mice with tamoxifen-inducible Cre transgenic lines...
  63. Molecular and Physiological Function of the Tubby Gene Family
    Juergen K Naggert; Fiscal Year: 2013
    ..hypothesis that mutations of TULP3 will lead to obesity and retinal disease in the adult animal by generating a tamoxifen inducible allele of TULP3...
  64. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2003
    ..evidence indicate that estrogens promote breast cancer, Selective estrogen receptor modulators (SERMs), such as tamoxifen are first-line drugs used as adjuvant therapy for preventing recurrences and reducing mortality in women with a ..
  65. TAMOXIFEN--RISK OF MI, STROKE AND VENOUS THROMBOEMBOLISM
    Leslie Bernstein; Fiscal Year: 2001
    DESCRIPTION: (Adapted from Investigator's Abstract) Tamoxifen, a synthetic, non-steroidal antiestrogen in breast tissue, has been successfully used to treat breast cancer and is now being evaluated as a breast cancer chemopreventive ..
  66. Dietary Isoflavones, Tamoxifen, and Tumor Growth
    William Helferich; Fiscal Year: 2005
    ..If a woman has E-responsive breast cancer it is likely that she is receiving antiestrogen tamoxifen (TAM) therapy...
  67. CHEMOPREVENTION OF MAMMARY TUMORS BY TAMOXIFEN AND SOY
    Andreas Constantinou; Fiscal Year: 2002
    b>Tamoxifen as an ERalpha antagonist is an effective chemopreventive agent against breast cancer. The soy isoflavones genistein and daidzein are ER (alpha and beta) agonists and antagonists...
  68. Interactions Between Dietary Soy Components & Tamoxifen
    Jin Rong Zhou; Fiscal Year: 2003
    This proposal is focused on the interactive effects between soybean phytochemicals and tamoxifen (TAM) on breast cancer (BRCA)...
  69. STROMAL INFLUENCES ON BREAST CANCER PROGRESSION
    SANDRA MCLESKEY; Fiscal Year: 1999
    ..produce large, progressively growing tumors which are invasive, frequently metastatic and growth-stimulated by tamoxifen, an estrogen antagonist...
  70. Interactions between SERMs, soy and black cohosh
    Heather Shaw; Fiscal Year: 2007
    b>Tamoxifen is the most commonly used selective estrogen receptor modulator (SERM) in the treatment and prevention of breast cancer...
  71. Mechanism(s)of antitumor action of tamoxifen and soy
    Andreas Constantinou; Fiscal Year: 2003
    b>Tamoxifen, an estrogen receptor alpha (ERa) antagonist, is an effective chemopreventive agent against breast cancer. The soy phytoestrogens genistein and daidzein selectively bind to ERbeta...
  72. A Pilot Trial of Oral Melatonin Supplementation in Breast Cancer Survivors
    Eva Schernhammer; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Although tamoxifen has been approved by the FDA to reduce breast cancer incidence, concern remains regarding the widespread use of tamoxifen among healthy women because of its ..
  73. Treatment effects on hormones in the breast
    Robert Chatterton; Fiscal Year: 2005
    Over 30% of estrogen receptor positive (ER+) tumors are not prevented by tamoxifen prophylaxis...
  74. TAMOXIFEN AND RETINOIC ACID EFFECT ON THE UTERUS
    Kenneth Nephew; Fiscal Year: 2000
    ..Two thirds of the breast cancers are manifested in the post-menopausal period. Cancer prophylaxis trials for tamoxifen are currently underway on groups of women at high risk for developing breast cancer...
  75. Phosphorylation of Estrogen Receptor and Coregulators
    BRIAN ROWAN; Fiscal Year: 2009
    b>Tamoxifen is the major SERM (Selective Estrogen Receptor Modulator) used in breast cancer. However, patient response to tamoxifen is variable and tamoxifen exhibits serious estrogen-like side effects in nontarget tissues such as uterus...
  76. Biomarker modulation/COX-2 inhibitor/Breast Cancer
    Banu Arun; Fiscal Year: 2003
    ..In that effort, a large phase III chemoprevention trial of tamoxifen showed a reduced incidence of estrogen receptor (ER) positive breast cancer...
  77. Pharmacogenetics of Tamoxifen and Chemotherapies and Risk of Contralateral Breast
    Jane C Figueiredo; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Adjuvant chemotherapy and tamoxifen have been shown to reduce the risk of contralateral breast cancer (CBC) among women with a previous history of breast cancer...
  78. TAMOXIFEN MODULATES OSTEOCLAST CA++/CALMODULIN SIGNALING
    Jay McDonald; Fiscal Year: 2001
    ..In the first funding period, we determined that tamoxifen inhibits mature osteoclast activity by disrupting Ca/2+/calmodulin and protein kinase C signaling cascades by a ..